Amarin Corp Plc (AMRN)

[alm2]

Excellent analysis- from earlier posts - see Fish and Richardson article-there appears opportunity to seek injunction to prevent infringement of the reduce it label patents which are not affected by the D.C./FC decision
If granted the generics would have to cease selling

Amarin would lose nothing in attempting to obtain such an injunction save the legal fees involved - the gain would be immense - such goes without saying

Evidence could be carefully collected from various sources as to how generic sales infringe on the reduce it patents
The generics will of course be aware of this risk to them and it may colour their enthusiasm
Alm